

United States Humanized Mice Model Market By Type (Genetic Humanized Mice Model, Cell-based Humanized Mice Model), By Application (Oncology Studies, Immunology and Inflammation Studies, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations), By Region, Competition, Forecast and Opportunities, 2018-2028F

<https://marketpublishers.com/r/UDA8AD642408EN.html>

Date: October 2023

Pages: 70

Price: US\$ 3,500.00 (Single User License)

ID: UDA8AD642408EN

Abstracts

United States Humanized Mice Model Market is anticipated to project steady growth in the forecast period. A Humanized Mice Model, also known as a Humanized Mouse Model, refers to a specialized research model where mice are genetically modified to possess human genes, cells, tissues, or microorganisms. This groundbreaking technique serves as an indispensable tool in the field of biomedical research, specifically in the study of human diseases. By introducing human elements into mice, scientists gain the ability to closely observe and analyze disease progression, as well as assess the efficacy of potential treatments, all within a living organism. This innovative approach not only provides valuable insights into the mechanisms underlying human diseases but also offers a means to test experimental therapies without the ethical concerns associated with human experimentation. Through the utilization of Humanized Mice Models, researchers are able to delve deeper into the complexities of human health and make significant strides towards improving medical treatments and interventions.

Key Market Drivers

Increasing Need for Personalized Medicine

The escalating need for personalized medicine is predicted to surge the demand for humanized mice models in the United States. Personalized medicine, with its tailor-made approach, relies heavily on the concept of individual variability in genes, environment, and lifestyle. It necessitates models that can closely mirror human physiological and pathological conditions, which is where humanized mice models become invaluable. These models are genetically modified mice which carry functioning human genes, cells, tissues, and/or organs. Their human-like immune responses make them an ideal tool for studying the efficacy of personalized therapies, hence, directly influencing their demand. As the United States continues to pioneer advancements in personalized medicine, the demand for more accurate predictive models like humanized mice is anticipated to significantly rise to support the development of more precise, effective treatments. The growth of personalized medicine therefore directly correlates with the increased need for humanized mice, reinforcing the crucial role these models play in medical research and development.

Advancement In Gene Editing Tools

The advancement in gene-editing tools, predominantly the CRISPR-Cas9 system, is expected to drive the demand for Humanized Mice Models (HMMs) in the United States significantly. HMMs have become invaluable in biomedical research for modeling human diseases, due to the genetic similarity between humans and mice. With the advent of precise and efficient gene-editing tools like CRISPR, it is now possible to modify mice genomes to mimic human physiological and pathological processes more accurately. These advancements allow for more nuanced exploration of human diseases, especially in the realm of oncology, immunology, and genetic disorders, fueling the demand for HMMs. Furthermore, the evolution of these technologies has also made it feasible to humanize mice with patient-specific cells, pushing personalized medicine forward. As these capabilities increase, so does the need for HMMs in cutting-edge biomedical research, driving their demand in the United States. The backing of substantial federal research funding and the presence of major pharmaceutical and biotech companies in the U.S. will further compound this effect, emphasizing the role of gene-editing advancements in the increased demand for HMMs.

Increasing Number of Research Activities Involving Humanized Models

The growing number of research activities involving humanized models in the United

States is projected to significantly fuel the demand for Humanized Mice Models. These models offer a unique platform for understanding human immunology, diseases, and therapeutic responses by replicating human-specific responses. Progress in genetic engineering technologies has led to the development of humanized mice models that carry functional human genes, cells, tissues, and organs, thereby providing more accuracy in research outcomes. Studies involving these models have become instrumental in fields like oncology, infectious diseases, and immunology. The increased demand is also attributable to their role in the development and testing of immunotherapies and regenerative medicine, where humanized mice have proven critical for the preclinical evaluation of the efficacy and safety of novel treatments. Furthermore, the ongoing R&D investments and government funding for biomedical research are expected to contribute to the increased adoption of these models. As the number of these research activities continues to rise in the United States, so too will the demand for Humanized Mice Models.

Increasing Number Of R&D Activities in Pharmaceutical & Biotechnology Companies

The pharmaceutical and biotechnology industries in the United States are witnessing an unprecedented surge in research and development (R&D) activities. This expansion is set to significantly drive demand for Humanized Mice Models (HMMs), an essential tool used in these sectors. HMMs, which incorporate human cells, tissues, or genes, are utilized extensively in drug development processes, helping scientists study disease mechanisms and test novel therapeutics. As R&D activities ramp up, more biomedical investigations involving human-specific responses are being initiated, necessitating the use of HMMs. Furthermore, the escalating focus on personalized medicine, fueled by the promise of gene therapies and innovative oncology treatments, underscores the need for these models. The ability of HMMs to mimic human immune response and disease progression facilitates a more accurate prediction of drug efficacy and safety, which is paramount in the era of individualized treatment. Therefore, as the intensity of R&D in the U.S. pharmaceutical and biotechnology sectors escalates, so too does the need for Humanized Mice Models, cementing their role at the forefront of groundbreaking medical research.

Key Market Challenges

High Costs Associated with Development of Humanized Mice Models

The high costs associated with the development of Humanized Mice Models (HMMs) may curtail their demand in the United States. Creating HMMs demands sophisticated

biotechnological processes and highly skilled professionals, factors that contribute significantly to the overall cost. Moreover, maintaining these models, involving specialized housing and care, adds to the expenditure. These escalated costs may act as a deterrent, especially for smaller research entities with limited budgets. Furthermore, securing funding for research involving HMMs can be challenging due to its high cost, which may deter potential researchers. This financial strain could prompt researchers to seek alternative, more cost-effective models or methodologies for their studies. As a result, the high development and maintenance costs associated with HMMs are expected to decrease their demand in the U.S., potentially slowing advancements in this critical area of medical research. The onus, then, is on both public and private sectors to address these cost issues, possibly through funding initiatives or cost-effective innovation, to maintain the momentum of research involving HMMs.

Stringent Regulations and Laws Formulated for The Ethical Use Of Animals

Stringent regulations and laws formulated for the ethical use of animals are expected to decrease the demand for humanized mice models in the United States. The public concern over animal welfare has led to the development and implementation of comprehensive legislation and guidelines that govern the use of animals in scientific research. These measures enforce ethical considerations, demanding the minimization of animal suffering and the prioritization of alternatives whenever possible. Consequently, the high ethical standards established by these laws and regulations may discourage the use of humanized mice models in favor of alternative, non-animal-based methods. For instance, advancements in in-vitro techniques and computational models are offering promising alternatives that align more closely with ethical guidelines. Additionally, public accountability and the potential reputational damage that can result from perceived unethical practices further contribute to the declining demand. Thus, the combination of regulatory constraints, advancing technologies, and public sentiment is likely to see a reduction in the use of humanized mice models within the United States.

Key Market Trends

Increased Use in Oncology Research

The increased use of humanized mice models in oncology research is expected to boost their demand in the United States. This surge is attributed to the mouse models' exceptional ability to mimic human physiology and immune system responses, thus providing a valuable platform for cancer research. Oncologists are using these models

to study the diversity of human cancers, understand tumor progression, and explore potential treatment modalities. The rise in cancer cases nationwide further intensifies the need for innovative research tools, putting humanized mice models at the forefront. Additionally, advancements in genetic engineering techniques have improved the quality and diversity of these models, making them more appealing for complex cancer research. With the United States being a global leader in medical research, the demand for these models is expected to grow. This surge is further amplified by increased funding for cancer research and the steady development of customized models for specific cancer types. Consequently, the utilization of humanized mice models in oncology research creates a robust demand in the United States, driving the market's growth.

Increased Preclinical Drug Testing

The demand for Humanized Mice Models in the United States is predicted to rise significantly due to an increase in preclinical drug testing. As drug discovery and development processes are becoming more complex, the need for reliable and predictive models is paramount. Humanized Mice Models, with their human-like immune system responses, have proven to be invaluable tools in preclinical stages, especially in oncology, immunology, infectious diseases, and autoimmunity studies. They offer a robust platform for testing drug efficacy, safety, and pharmacokinetics before advancing to human trials. The growing prevalence of diseases, coupled with an upsurge in biotechnological and pharmaceutical R&D investments, is expected to drive the need for preclinical trials, subsequently fueling the demand for Humanized Mice Models. Moreover, the recent FDA guidelines encouraging the adoption of such models for early toxicity and efficacy evaluation are likely to further stimulate the market growth. Consequently, as preclinical drug testing expands, the reliance on Humanized Mice Models is poised to increase, catering to the demand for more realistic and informative preclinical study outcomes.

Segmental Insights

Type Insights

Based on the Type, the Genetic Humanized Mice Model is projected to dominate the United States Humanized Mice Model Market. These models have gained significant traction due to their enhanced capabilities in mimicking the complex human immune system, enabling more accurate preclinical research and efficient drug development. The increasing utilization of Genetic Humanized Mice Models in various therapeutic

areas, such as oncology, immunology, and infectious diseases, further contributes to their growing adoption and dominance in the market. Moreover, the Genetic Humanized Mice Models exhibit a high degree of genetic similarity to humans, allowing researchers to study the effects of specific genes and genetic variations on disease progression and treatment response. This level of precision and relevance in modeling human physiology and disease mechanisms positions Genetic Humanized Mice Models as invaluable tools in advancing biomedical research and accelerating the development of novel therapies. With their ability to provide a closer representation of human biology and pathophysiology, these models pave the way for groundbreaking discoveries and breakthroughs in the field of medicine.

Application Insights

Based on the Application, in the United States Humanized Mice Model Market Oncology Studies that are anticipated to hold the largest market share. This is largely due to the critical importance of these models in cancer research. They provide invaluable insight into tumorigenesis, metastasis, and potential therapeutic interventions, aiding scientists in developing novel treatment approaches. Moreover, these models also enable the evaluation of immunotherapies, which are increasingly becoming integral in cancer treatment strategies. By studying the interaction between the immune system and cancer cells, researchers can identify promising immunotherapeutic targets and develop personalized treatment regimens. Consequently, the Oncology Studies segment is expected to maintain its dominant position in the foreseeable future, driving advancements in cancer research and treatment.

Regional Insights

The North-East region of the United States is projected to dominate the Humanized Mice Model Market. This is primarily due to the region's robust research and development infrastructure, which includes world-class academic institutions and cutting-edge laboratories. These institutions not only provide state-of-the-art facilities but also foster a collaborative environment that attracts top researchers and scientists from around the world. The North-East is home to a high concentration of leading pharmaceutical and biotechnology companies that actively engage in partnerships and collaborations with academic institutions, further driving innovation in the field of biomedical research. Additionally, the region benefits from substantial government funding dedicated to advancing scientific discoveries and breakthroughs, ensuring a continuous flow of resources for research and development. These factors collectively position the North-East as a frontrunner in the Humanized Mice Model Market, driving

advancements in preclinical research, therapeutic development, and contributing to the overall growth of the biotech industry in the region.

Key Market Players

Charles River Laboratories International, Inc.

The Jackson Laboratory

Taconic Biosciences Inc.

Hera BioLabs

Ingenious Targeting Laboratory Inc.

Champions Oncology, Inc.

Yecuris Corporation

Report Scope:

In this report, the United States Humanized Mice Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

United States Humanized Mice Model Market, By Type:

Genetic Humanized Mice Model

Cell-based Humanized Mice Model

United States Humanized Mice Model Market, By Application:

Oncology Studies

Immunology and Inflammation Studies

Others

United States Humanized Mice Model Market, By End User:

Pharmaceutical & Biotechnology Companies

Academic & Research Institutes

Contract Research Organizations

United States Humanized Mice Model Market, By Region:

Northeast Region

Midwest Region

West Region

South Region

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the United States Humanized Mice Model Market.

Available Customizations:

United States Humanized Mice Model Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. UNITED STATES HUMANIZED MICE MODEL MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Type (Genetic Humanized Mice Model, Cell-based Humanized Mice Model)
 - 5.2.2. By Application (Oncology Studies, Immunology and Inflammation Studies, Others)

5.2.3. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations)

5.2.4. By Region

5.2.5. By Company (2022)

5.3. Market Map

6. NORTH-EAST HUMANIZED MICE MODEL MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Type

6.2.2. By Application

6.2.3. By End User

7. MID-WEST HUMANIZED MICE MODEL MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Type

7.2.2. By Application

7.2.3. By End User

8. WEST HUMANIZED MICE MODEL MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Type

8.2.2. By Application

8.2.3. By End User

9. SOUTH HUMANIZED MICE MODEL MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Type

9.2.2. By Application

9.2.3. By End User

10. MARKET DYNAMICS

10.1. Drivers

10.2. Challenges

11. MARKET TRENDS & DEVELOPMENTS

11.1. Recent Development

11.2. Mergers & Acquisitions

11.3. Product Launches

12. POLICY & REGULATORY LANDSCAPE

13. UNITED STATES ECONOMIC PROFILE

14. UNITED STATES HUMANIZED MICE MODEL MARKET: SWOT ANALYSIS

15. PORTER'S FIVE FORCES ANALYSIS

15.1. Competition in the Industry

15.2. Potential of New Entrants

15.3. Power of Suppliers

15.4. Power of Customers

15.5. Threat of Substitute Products

16. COMPETITIVE LANDSCAPE

16.1. Charles River Laboratories International, Inc.

16.1.1. Business Overview

16.1.2. Product Offerings

16.1.3. Recent Developments

16.1.4. Financials (As Reported)

16.1.5. Key Personnel

- 16.2. The Jackson Laboratory
- 16.3. Taconic Biosciences Inc.
- 16.4. Hera BioLabs
- 16.5. Ingenious Targeting Laboratory Inc.
- 16.6. Champions Oncology, Inc.
- 16.7. Yecuris Corporation

17. STRATEGIC RECOMMENDATIONS

18. ABOUT US & DISCLAIMER

I would like to order

Product name: United States Humanized Mice Model Market By Type (Genetic Humanized Mice Model, Cell-based Humanized Mice Model), By Application (Oncology Studies, Immunology and Inflammation Studies, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations), By Region, Competition, Forecast and Opportunities, 2018-2028F

Product link: <https://marketpublishers.com/r/UDA8AD642408EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UDA8AD642408EN.html>